European Radiology:利用人工智能预测COVID-19患者的疾病进展。

2022-01-20 shaosai MedSci原创

2019年冠状病毒病(COVID-19)可引起严重的呼吸道并发症,例如急性呼吸衰竭,并给全世界的医疗系统带来巨大压力。

2019年冠状病毒病(COVID-19引起严重的呼吸道并发症,例如急性呼吸衰竭,并给全世界的医疗系统带来巨大压力。例如,由COVID-19引起的急性呼吸窘迫综合症(ARDS)患者往往需要插管和重症监护室(ICU)的护理。由于机械呼吸机和ICU护理的短缺,准确和及时地预测COVID-19患者ARDS的发生至关重要。在COVID-19中,大部分患者的病情都会进展,特别是那些有肥胖、心血管疾病、慢性肺病、高血压或癌症等合并症的患者更为严重。然而,预测一个COVID-19患者何时会发展成危重病症仍是一个挑战。

除了患者的人口统计学和实验室参数外,胸部CT在区分COVID-19的重症和非重症病例方面发挥了重要作用。病情严重的患者一般会有弥漫性多叶受累、胸腔积液、合并症、支气管壁增厚、肺部通气不良胸部CT表现。由于COVID-19在胸部CT上的特征性表现,人工智能(AI)在为患者归纳疾病严重程度状态和预后方面具有较高的实用性。

近日,发表在European Radiology杂志的一项研究利用胸部CT和临床数据,开发一个人工智能(AI)系统来预测COVID-19患者未来的病情恶化提供了影像学技术支持

本研究开发了一个时间-事件分析框架下的人工智能(AI)系统,整合胸部CT和临床数据用于预测COVID-19患者未来恶化为危重病的风险。 

本研究纳入了1,051名RT-PCR确认的COVID-19患者和胸部CT的多机构国际队列。其中282名患者出现了危重症,其定义是需要入住ICU和/或机械通气和/或在住院期间出现死亡。人工智能系统在预测个别COVID-19患者的危重病方面达到了0.80的C-指数。人工智能系统成功地将患者分为高风险组和低风险组,并有不同的进展风险(P < 0.0001)。 

 

 a-c 不同截值(3天、5天和7天)的时间依赖性ROC-AUCs和风险分层的亚组生存曲线。进展预测和联合进展预测。y轴是生存概率,代表没有进展到关键事件的概率。生存曲线中的 "+"表示删减的病人。这些分层结果的风险表也列在该图的底部

基于CT成像和临床数据的人工智能可进行COVID-19患者未来恶化为危重疾病的风险预测。随着这项技术的进一步发展,医疗机构可利用人工智能基于疾病严重程度和进展风险预测的高风险患者进行风险分层,使该类患者能够随时分配适当的治疗、设备和其他必要的资源,提高患者的预后及生存率

原文出处

Robin Wang,Zhicheng Jiao,Li Yang,et al

.Artificial intelligence for prediction of COVID-19 progression using CT imaging and clinical data.DOI:10.1007/s00330-021-08049-8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1729321, encodeId=93601e2932185, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 27 08:03:34 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907781, encodeId=a789190e78147, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 05 18:03:34 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297566, encodeId=df8b129e56615, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Jan 22 06:03:34 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186633, encodeId=8a2711866336c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 20 23:11:53 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186623, encodeId=4c991186623b5, content=学习了,非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/01/1078d2e0242b103ff542afeb81c7ba21.jpg, createdBy=eb5f5271958, createdName=1354824f40m, createdTime=Thu Jan 20 22:33:37 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-11-27 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1729321, encodeId=93601e2932185, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 27 08:03:34 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907781, encodeId=a789190e78147, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 05 18:03:34 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297566, encodeId=df8b129e56615, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Jan 22 06:03:34 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186633, encodeId=8a2711866336c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 20 23:11:53 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186623, encodeId=4c991186623b5, content=学习了,非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/01/1078d2e0242b103ff542afeb81c7ba21.jpg, createdBy=eb5f5271958, createdName=1354824f40m, createdTime=Thu Jan 20 22:33:37 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1729321, encodeId=93601e2932185, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 27 08:03:34 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907781, encodeId=a789190e78147, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 05 18:03:34 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297566, encodeId=df8b129e56615, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Jan 22 06:03:34 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186633, encodeId=8a2711866336c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 20 23:11:53 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186623, encodeId=4c991186623b5, content=学习了,非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/01/1078d2e0242b103ff542afeb81c7ba21.jpg, createdBy=eb5f5271958, createdName=1354824f40m, createdTime=Thu Jan 20 22:33:37 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1729321, encodeId=93601e2932185, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 27 08:03:34 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907781, encodeId=a789190e78147, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 05 18:03:34 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297566, encodeId=df8b129e56615, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Jan 22 06:03:34 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186633, encodeId=8a2711866336c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 20 23:11:53 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186623, encodeId=4c991186623b5, content=学习了,非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/01/1078d2e0242b103ff542afeb81c7ba21.jpg, createdBy=eb5f5271958, createdName=1354824f40m, createdTime=Thu Jan 20 22:33:37 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-01-20 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1729321, encodeId=93601e2932185, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 27 08:03:34 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907781, encodeId=a789190e78147, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 05 18:03:34 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297566, encodeId=df8b129e56615, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Jan 22 06:03:34 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186633, encodeId=8a2711866336c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jan 20 23:11:53 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186623, encodeId=4c991186623b5, content=学习了,非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/01/1078d2e0242b103ff542afeb81c7ba21.jpg, createdBy=eb5f5271958, createdName=1354824f40m, createdTime=Thu Jan 20 22:33:37 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-01-20 1354824f40m

    学习了,非常实用

    0

相关资讯

J Clin Oncol:基于乳腺X线检查的乳腺癌风险预测人工智能模型

乳腺癌在全球女性癌症中的发病率为24.2%,位居女性癌症的首位,其中52.9%发生在发展中国家

Radiology:人工智能,使自动检测和分类MRI腰椎中央管、侧隐窝、神经孔狭窄成为可能

腰椎管狭窄症(LSS)是一种十分常见的疾病,极大影响人们的生活质量。大多数LSS患者表现为下背部疼痛,这也是寻求治疗的主要原因。

PRS:人工智能对整容手术后减龄的认知有助于预估术后患者满意度

患者行整容手术主要是为了显得更年轻、更精神、更有吸引力。研究显示,整容手术后的满意度很高。然而,感知的面部年龄减少与患者满意度的相关程度尚不清楚。面部手术效果对患者影响的量化一直是整形学科讨论的主题。

European Radiology:人工智能,使胸片上肺部4类结节无处遁形!

肺癌是世界上死亡率最高的癌症,早期诊断及治疗是影响患者生存的有力的因素之一。现阶段,胸片仍然是最常选择的成像方式,为更多人群提供了早期发现肺癌的机会。

Radiology:人工智能技术在x线片骨折识别中的应用

在各种临床环境下,使用x线片明确骨折的存在是影像科最常见的工作之一。骨折的漏诊在影像科十分常见,这将延误患者的治疗,甚至造成严重的临床后果。因此,对骨折的准确识别及判断对临床至关重要。

IJNS:人工智能技术在护理研究中的应用

基于人工智能技术在护理中应用的研究主要处于技术发展的早期阶段,评估技术实施和临床结果之间存在明显差距。